Stock VIVE VIVESTO AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Vivesto AB

Equities

VIVE

SE0000722365

Market Closed - Nasdaq Stockholm
Other stock markets
 11:50:45 08/05/2024 BST 		5-day change 1st Jan Change
0.303 SEK +3.24% Intraday chart for Vivesto AB +8.02% -25.64%
03-26 Transcript : Vivesto AB - Special Call
03-07 Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial
Vivesto AB Reports Earnings Results for the Full Year Ended December 31, 2023
Vivesto's International Patent Application for XR-18 Receives Positive Decision
Vivesto Gains on Receipt of US Approval for Pilot Clinical Trial of Drug Candidate Paccal Vet
Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient Recruitment
Vivesto AB Reports Positive Preclinical Data Supporting Continued Development of Cantrixil
Vivesto AB Announces Composition of Nomination Committee
Vivesto Abandons Apealea Partnership with Elevar Therapeutics
Vivesto AB and Elevar Therapeutics Inc. Sign Agreement Ending Apealea®? Partnership
Vivesto AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Pharmaceutical Group Vivesto to Delist from Frankfurt Bourse
Vivesto AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Vivesto Halts Patient Enrollment in Phase 1b Study for Prostate Cancer Treatment
Vivesto AB Announces Early Termination of Patient Enrollment in the Investigator-Initiated Phase 1B Docetaxel Micellar Study
Easing Eurozone Inflation Buoys EU Stocks to Higher Close on Friday
Vivesto Jumps 12% on Successful US FDA Meeting for Veterinary Oncology Drug Candidate
Vivesto AB Announces Positive Paccal Vet FDA Pre-Submission Meeting
Vivesto AB Reports Earnings Results for the First Quarter Ended March 31, 2023
Vivesto AB Initiates Clinical Development of Paccal Vet in Veterinary Oncology
Vivesto AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIVE Stock
  4. News Vivesto AB
  5. Other languages